Molnupiravir reduces long-term COVID-19 symptoms but shows limited impact on hospitalizations

Molnupiravir treatment for COVID-19 shows modest long-term benefits, reducing symptoms and improving well-being at three and six months. However, the differences were small, with no impact on hospitalization rates.

Emteq Labs Unveils World’s First Emotion-Sensing Eyewear for Health and Beyond

What You Should Know: – Emteq Labs, a pioneer in emotion-recognition wearable technology, has announced the upcoming launch of Sense, groundbreaking eyewear that can detect

October 16, 2024

Early treatment with convalescent plasma may reduce risk of long COVID

Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19

September 20, 2023

Brightside Health Expand Telemental Health Services to Teens

What You Should Know: – True to its mission of expanding access to care, Brightside Health now offers mental health services for teens aged 13 to

September 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.